New pill HRS-7535 aims to tame type 2 diabetes

NCT ID NCT06672172

Completed Disease control Sponsor: Shandong Suncadia Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 3 trial tested three doses of the oral drug HRS-7535 against a placebo in 284 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. The main goal was to see if HRS-7535 could lower HbA1c (a measure of average blood sugar) over 32 weeks. Researchers also tracked weight changes and how many participants reached target blood sugar levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-7535 tablet (a drug to lower blood sugar)
What this could lead to: If successful, HRS-7535 could offer a new oral medication option to help control blood sugar and possibly reduce weight in people with type 2 diabetes.
What could go wrong: This is a completed phase 3 trial, but results are not yet public. The drug may not prove significantly better than placebo, and side effects are possible. It is not a cure and requires ongoing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Show contact details

Locations

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.